The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed tr...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!